Signalling pathways and molecular interactions of NOD1 and NOD2

被引:0
|
作者
Warren Strober
Peter J. Murray
Atsushi Kitani
Tomohiro Watanabe
机构
[1] Mucosal Immunity Section,Department of Infectious Diseases
[2] Laboratory of Host Defenses,undefined
[3] National Institute of Allergy and Infectious Diseases,undefined
[4] National Institutes of Health,undefined
[5] Building 10 CRC,undefined
[6] 5W3940,undefined
[7] St. Jude Children's Research Hospital,undefined
[8] 332 North Lauderdale,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The nucleotide-binding oligomerization domain (NOD) proteins NOD1 and NOD2 are members of a recently described protein family, the NACHT (domain present in NAIP, CIITA, HET-E and TP1)-LRR (leucine-rich repeat) family (NLR family). Proteins in this family are structurally related cytosolic proteins with LRR domains (which bind microbial ligands) that are similar to those found in Toll-like receptors (TLRs). As such, NOD1 and NOD2 have important roles in innate immunity.NOD1 and NOD2 are expressed by epithelial cells and antigen-presenting cells. Through their LRR domain, they recognize conserved components of the bacterial cell-wall constituent peptidoglyan: NOD1 binds γ-D-glutamyl-meso-diaminopimelic acid, and NOD2 binds muramyl dipeptide. Such recognition leads to the oligomerization of NOD1 and NOD2, followed by activation of the downstream effector molecule RICK (receptor-interacting serine/threonine kinase). This, in turn, leads to activation of nuclear factor-κB and other effector pathways.The outcome of NOD2 signalling is complex. NOD2 can function as a mediator of innate immunity by itself, but it might also function as a modifier of innate immunity that results from TLR activity. So, there is evidence that NOD2 downregulates T-helper-1-cell responses (that is, interleukin-12 (IL-12) production) that are induced after peptidoglycan binds TLR2. By contrast, there is also evidence that NOD2 upregulates tumour-necrosis factor, IL-6 and CXC-chemokine ligand 8 (CXCL8; also known as IL-8) production induced by signalling through a broad range of TLRs.Whereas NOD1 is broadly expressed by intestinal epithelial cells, NOD2 is expressed mainly by Paneth cells, which are located at the base of the epithelial crypts. In these cells, NOD2 might be an important inducer of α-defensins, which are antibacterial peptides that have a role in host defence at the epithelial interface.Mutations in the LRR domain of the caspase-recruitment domain 15 gene (CARD15; which encodes NOD2) are associated with the development of Crohn's disease, whereas mutations in the NOD of NOD2 can lead to the development of Blau syndrome. On the basis of studies of mice that lack Card15 and mice with a mutated Card15 'knocked-in', three explanations for these associations are under consideration. In each case, the proposed mechanism leads to a dysregulated innate immune response to components of the microbial flora of the gut, so this highlights the normal role of NOD2 in mucosal homeostasis.NOD1 is activated by microbial components that gain entry to the cytosol of epithelial cells. Such activation leads to the production of chemokines and possibly other host-defence factors against potential gut pathogens. So, mice with defective NOD1 function are more susceptible to infection with Helicobacter pylori, and NOD1 might be a factor in human diseases that involve this organism.
引用
收藏
页码:9 / 20
页数:11
相关论文
共 50 条
  • [1] Signalling pathways and molecular interactions of NOD1 and NOD2
    Strober, W
    Murray, PJ
    Kitani, A
    Watanabe, T
    [J]. NATURE REVIEWS IMMUNOLOGY, 2006, 6 (01) : 9 - 20
  • [2] NOD1 and NOD2 signalling links ER stress with inflammation
    A. Marijke Keestra-Gounder
    Mariana X. Byndloss
    Núbia Seyffert
    Briana M. Young
    Alfredo Chávez-Arroyo
    April Y. Tsai
    Stephanie A. Cevallos
    Maria G. Winter
    Oanh H. Pham
    Connor R. Tiffany
    Maarten F. de Jong
    Tobias Kerrinnes
    Resmi Ravindran
    Paul A. Luciw
    Stephen J. McSorley
    Andreas J. Bäumler
    Renée M. Tsolis
    [J]. Nature, 2016, 532 : 394 - 397
  • [3] Pathway Selection by Nod1 and Nod2
    Heul, A. Ver
    Ramaswamy, S.
    Piper, R.
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2011, 22
  • [4] Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2
    Girardin, SE
    Travassos, LH
    Hervé, M
    Blanot, D
    Boneca, IG
    Philpott, DJ
    Sansonetti, PJ
    Mengin-Lecreulx, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) : 41702 - 41708
  • [5] Cross-talk of Nod1 and Nod2 signaling pathways with IFNγ
    Duerr, Claudia
    Fritz, Joerg
    [J]. JOURNAL OF IMMUNOLOGY, 2012, 188
  • [6] NOD1 and NOD2 signaling in infection and inflammation
    Moreira, Lilian O.
    Zamboni, Dario S.
    [J]. FRONTIERS IN IMMUNOLOGY, 2012, 3
  • [7] Analgesic effects of NOD1 and NOD2 agonists
    Sato, Tadasu
    Shimauchi, Hidetoshi
    Endo, Yasuo
    Takada, Haruhiko
    [J]. INTERFACE ORAL HEALTH SCIENCE 2009, 2010, : 217 - +
  • [8] NOD1 and NOD2 in inflammation, immunity and disease
    Mukherjee, Tapas
    Hovingh, Elise Sofie
    Foerster, Elisabeth G.
    Abdel-Nour, Mena
    Philpott, Dana J.
    Girardin, Stephen E.
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2019, 670 : 69 - 81
  • [9] NOD1 and NOD2: Beyond Peptidoglycan Sensing
    Keestra-Gounder, A. Marijke
    Tsolis, Renee M.
    [J]. TRENDS IN IMMUNOLOGY, 2017, 38 (10) : 758 - 767
  • [10] NOD1 and NOD2 in inflammatory and infectious diseases
    Trindade, Bruno C.
    Chen, Grace Y.
    [J]. IMMUNOLOGICAL REVIEWS, 2020, 297 (01) : 139 - 161